Published in J Gastroenterol on April 26, 2007
HCV and oxidative stress in the liver. Viruses (2013) 1.28
Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C. Clin Exp Med (2016) 0.83
Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C. World J Gastroenterol (2010) 0.79
Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver. World J Gastroenterol (2015) 0.77
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (2004) 19.19
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood (2003) 5.11
Iron and chronic viral hepatitis. Hepatology (1997) 2.18
Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology (2002) 1.97
A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol (2004) 1.83
Orchestration of iron homeostasis. N Engl J Med (2005) 1.23
Upregulation of transferrin receptor 2 and ferroportin 1 mRNA in the liver of patients with chronic hepatitis C. J Gastroenterol Hepatol (2005) 0.91
Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gastroenterol (2005) 0.87
Therapy of hepatitis C: other options. Hepatology (1997) 0.85
MetaVelvet: an extension of Velvet assembler to de novo metagenome assembly from short sequence reads. Nucleic Acids Res (2012) 3.52
Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol (2008) 1.85
A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol (2004) 1.83
Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. J Gastroenterol Hepatol (2004) 1.77
Core protein of hepatitis C virus induces cardiomyopathy. Circ Res (2004) 1.73
Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol (2007) 1.73
Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology (2006) 1.60
Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med (2007) 1.59
Cognitive deficits in amyotrophic lateral sclerosis evaluated by event-related potentials. Clin Neurophysiol (2009) 1.46
Current state of Wilson disease patients in central Japan. Intern Med (2010) 1.45
Structures of the thermophilic F1-ATPase epsilon subunit suggesting ATP-regulated arm motion of its C-terminal domain in F1. Proc Natl Acad Sci U S A (2007) 1.30
Prospective evaluation of factors predicting difficulty and pain during sedation-free colonoscopy. Dis Colon Rectum (2005) 1.27
Assessing interactions in the brain with exact low-resolution electromagnetic tomography. Philos Trans A Math Phys Eng Sci (2011) 1.26
Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology (2002) 1.24
EphA receptor tyrosine kinases interact with co-expressed ephrin-A ligands in cis. Neurosci Res (2004) 1.19
Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med (2006) 1.18
Draxin, a repulsive guidance protein for spinal cord and forebrain commissures. Science (2009) 1.17
A novel association of duodenal atresia, malrotation, segmental dilatation of the colon, and anorectal malformation. Pediatr Surg Int (2009) 1.16
Sedation-free colonoscopy. Dis Colon Rectum (2005) 1.11
Draxin inhibits axonal outgrowth through the netrin receptor DCC. J Neurosci (2011) 1.06
Cessation of gastrulation is mediated by suppression of epithelial-mesenchymal transition at the ventral ectodermal ridge. Development (2007) 1.06
BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition (2007) 1.05
Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. J Gastroenterol Hepatol (2006) 1.02
High dose intravenous methylprednisolone resolves esophageal stricture resistant to balloon dilatation with intralesional injection of dexamethasone. Pediatr Surg Int (2008) 1.02
Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens (2007) 1.01
siRNA-resistance in treated HCV replicon cells is correlated with the development of specific HCV mutations. J Viral Hepat (2006) 1.01
Efficacy of long-term dietary restriction of total calories, fat, iron, and protein in patients with chronic hepatitis C virus. Nutrition (2004) 1.01
Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C. J Hepatol (2005) 1.00
Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2007) 0.99
[Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft--an EEG evaluation]. Rinsho Shinkeigaku (2003) 0.98
The crystal structure of a virus-like particle from the hyperthermophilic archaeon Pyrococcus furiosus provides insight into the evolution of viruses. J Mol Biol (2007) 0.97
A novel immunocompetent rat model of HCV infection and hepatitis. Gastroenterology (2005) 0.97
Cdk5/p35 and Rho-kinase mediate ephrin-A5-induced signaling in retinal ganglion cells. Mol Cell Neurosci (2003) 0.96
Binding of adiponectin and C1q in human serum, and clinical significance of the measurement of C1q-adiponectin / total adiponectin ratio. Metabolism (2012) 0.96
Recessive inheritance of population-specific intronic LINE-1 insertion causes a rotor syndrome phenotype. Hum Mutat (2015) 0.95
PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res (2004) 0.95
An isoflavone conjugate-hydrolyzing beta-glucosidase from the roots of soybean (Glycine max) seedlings: purification, gene cloning, phylogenetics, and cellular localization. J Biol Chem (2006) 0.94
Brown rice and its component, γ-oryzanol, attenuate the preference for high-fat diet by decreasing hypothalamic endoplasmic reticulum stress in mice. Diabetes (2012) 0.94
The structure of melon necrotic spot virus determined at 2.8 A resolution. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.92
Polymorphism of UDP-glucuronosyltransferase 1A7 gene: a possible new risk factor for lung cancer. Eur J Cancer (2005) 0.92
Association of cytokeratin 17 expression with differentiation in oral squamous cell carcinoma. J Cancer Res Clin Oncol (2012) 0.92
Upregulation of transferrin receptor 2 and ferroportin 1 mRNA in the liver of patients with chronic hepatitis C. J Gastroenterol Hepatol (2005) 0.91
Deletion of a chaperonin 60 beta gene leads to cell death in the Arabidopsis lesion initiation 1 mutant. Plant Cell Physiol (2003) 0.91
Tsukushi controls ectodermal patterning and neural crest specification in Xenopus by direct regulation of BMP4 and X-delta-1 activity. Development (2005) 0.91
Reactive nitrogen species mediate DNA damage in Helicobacter pylori-infected gastric mucosa. Helicobacter (2009) 0.91
Ephrin-B3-EphA4 interactions regulate the growth of specific thalamocortical axon populations in vitro. Eur J Neurosci (2002) 0.90
Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomarkers Prev (2009) 0.90
Neuronal stem/progenitor cells in the vertebrate eye. Dev Growth Differ (2008) 0.90